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A B S T R A C TObjective: To assess the cost-effectiveness of pharmaceutical care
(PC) intervention versus usual care (UC) in the management of type 2
diabetes. Methods: This study was a randomized, controlled study
with a 12-month patient follow-up in two Nigerian tertiary hospitals.
One hundred and ten patients were randomly assigned to each of the
“intervention” (PC) and the “control” (UC) groups. Patients in the UC
group received the usual/conventional care offered by the hospitals.
Patients in the PC group received UC and PC in the form of structural
self-care education and training for 12 months. The economic evalu-
ation was based on patients’ perspective. Costs of management of
individual complications were calculated from activities involved in
their management by using activity-based costing. The impact of the
interventions on quality of life was estimated by using the HUI23-
S4EN.40Q (Mark index 3) questionnaire. The primary outcomes were
incremental cost-utility ratio and net monetary beneﬁt. An intention-
to-treat approach was used. Two-sample comparisons were made by
using Student’s t tests for normally distributed variables data atsee front matter Copyright & 2013, International S
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1016/j.vhri.2013.06.009
rest: The authors have indicated that they have n
.adibe@unn.edu.ng; maxolpharmacia@yahoo.com.
ondence to: Maxwell O. Adibe, Department of Clini
eria.baseline, 6 months, and 12 months. Comparisons of proportions were
done by using the chi-square test. Results: The PC intervention led to
incremental cost and effect of Nigerian naira (NGN) 10,623 ($69) and
0.12 quality-adjusted life-year (QALY) gained, respectively, with an
associated incremental cost-utility ratio of NGN 88,525 ($571) per
QALY gained. In the cost-effectiveness acceptability curve, the prob-
ability that PC was more cost-effective than UC was 95% at the NGN
250,000 ($1613) per QALY gained threshold and 52% at the NGN 88,600
($572) per QALY gained threshold. Conclusions: The PC intervention
was very cost-effective among patients with type 2 diabetes at the
NGN 88,525 ($571.13) per QALY gained threshold, although consider-
able uncertainty surrounds these estimates.
Keywords: cost-effectiveness analysis, cost-utility analysis, Nigeria,
patients with type 2 diabetes, pharmaceutical care, usual care.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Analytic techniques used for economic evaluation in health care,
for example, cost-beneﬁt analysis, cost-effectiveness analysis,
and cost-consequences analysis, are designed to compare alter-
native courses of action in terms of costs and outcomes. The
choice of the technique depends on the decision the health
economists intend to inﬂuence. Quality-adjusted life-years
(QALYs) measure health as a combination of the duration of life
and the health-related quality of life [1]. The primary outcome of
a cost-utility analysis is the cost per QALY, or incremental cost-
utility ratio (ICUR), which is calculated as the difference in the
expected cost of two interventions divided by the difference in
the expected QALYs produced by the two interventions. The
results of a cost-utility analysis are compared with a threshold
incremental cost-effectiveness ratio (ICER); interventions with an
ICER below this threshold are funded, whereas those with an
ICER above the threshold tend not to be. Economic evaluationsusing QALYs as the principal measure of outcome, often termed
cost-utility studies, have become increasingly popular in the
literature and have also been adopted by a number of health
technology assessment agencies as the methodology of choice
[1].
Cost-utility analysis was developed to help decision makers
compare the value of alternative interventions that have very
different health beneﬁts, and it facilitates these comparisons
without recourse to placing monetary values on different health
states. Cost-utility analysis speciﬁes what value is attached to
speciﬁc health states, and thus increasingly facilitates the trans-
parency of resource allocation processes [2].
Cost-utility analysis was developed to address the problem of
conventional cost-effectiveness analysis, which did not allow
decision makers to compare the value of interventions for differ-
ent health problems. The utilities can now be obtained from
standardized and validated health status instruments, making
the evidence required to inform cost-utility analysis relativelyociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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with the cost of acquiring evidence on clinical effectiveness, and
indeed the cost of many of the treatments being reviewed [3].
Diabetes mellitus (DM) is associated with considerable morbid-
ity andmortality [4]. It is also a major risk factor for cardiovascular
disease, stroke, and kidney failure [5]. In Africa, DM probably has
the highest morbidity and mortality rates of all chronic non-
infective diseases [6].
DM was once regarded as a disease of the afﬂuent, but it is
now vastly visible as a growing health problem in developing
economics because almost 80% of diabetes deaths occur in low-
and middle-income countries [7,8]. The national standardized
prevalence rate of DM in Nigeria is 2.2%, while the crude
prevalence rate is 7.4% in those aged 45 years and above who
live in urban areas [9]. Global estimates of the prevalence of
diabetes showed that the prevalence of diabetes in Nigeria in
2010 was 4.7% (vs. 3.9% for world population) and that it would be
5.5% (vs. 4.3% for world population) in 2030 [10].
With the increasing demand for better management of type 2
diabetes, attention has focused on the potential beneﬁts of pharma-
ceutical care (PC) to improve patients’ health outcomes. Many PC
programs have been established in various countries to enhance
clinical outcomes and the health-related quality of life. These
programs were implemented by pharmacists, with the cooperation
of physicians and other health care professionals. PC and the
expanded role of pharmacists are associated with many positive
diabetes-related outcomes, including improved clinical measures
[11], improved patient and provider satisfaction [12,13], and
improved cost of management [12,14]. The pharmacists can, there-
fore, in collaboration with physicians and other health care profes-
sionals, contribute to an improvement in the quality of life of
patients with diabetes by informing and educating patients, answer-
ing their questions, and, at the same time, monitoring the outcomes
of their treatment [15]. In view of the above issues, the objective of
this study was to assess the cost-effectiveness of the PC intervention
in the management of type 2 diabetes versus usual care (UC).Methods
Study Design
This study was a randomized, controlled, and longitudinal pro-
spective study with a 12-month patient follow-up. The study
followed the Consolidated Health Economic Evaluation Reporting
Standards guideline for reporting economic evaluation of inter-
ventions [16]. The study protocol was approved by the Research
Ethical Committees of the University of Nigeria Teaching Hospi-
tal, Ituku Ozalla, and Nnamdi Azikiwe University Teaching
Hospital, Nnewi, in which this study was conducted. These
hospitals are tertiary hospitals that serve as referral centers to
most of the hospitals in the southeastern part of Nigeria.
Inclusion Criteria
Patients with type 2 DM who fulﬁlled the entrance criteria were
identiﬁed and included in the study. Inclusion criteria included
patients with type 2 diabetes who were on oral hypoglycemic
therapy and provided written informed consent in addition to
willingness to abide by the rules of the study and being certiﬁed
ﬁt to take part by the consulting physician.
Exclusion criteria were patients who were diagnosed with type 1
diabetes (to avoid complexity in the scope of the study), patients who
were younger than 18 years (they are legally regarded as dependents
and consequently they cannot take decisions of their own), patients
who were pregnant (they are generally not allowed to participate in a
study of this nature by the institutions used for the study), andpatients who expressed willingness to withdraw from the study
(participation is voluntary). The sample size determination showed
that a sample size of at least 104 patients was required in each of the
control and intervention groups [17]. Based on these data, to ensure
sufﬁcient statistical power and to account for “dropouts” during the
study, a target sample size of 220 patients was recruited (110 patients
from each of the hospitals). The folders of the 110 selected patients in
each hospital were assigned numbers 1 to 110, which represented an
individual patient. Patients were randomly assigned to one of two
groups (intervention group or control group) on the basis of the
number assigned to their folders by using online “random sequence
generator” [18] with sequence boundaries of 1 to 110 (boundaries
inclusive) set in a two-column format: the ﬁrst column was a priori
designated to the intervention group PC (55 patients) and the second
column to the control group UC (55 patients).
Patients in the UC group received the usual/conventional care
offered by the hospitals, which included hospital visits on appoint-
ment or on a sick day, consultations with physicians, prescription of
drugs and routine laboratory tests, review of diagnosis and medi-
cations, reﬁlling of prescriptions by patients, and referral. This UC
was offered with education/training of the patients in an uncoordi-
nated manner and without structured educational materials.
Patients in the PC group received UC and PC for 12 months on
monthly schedule. This additional PC included a stepwise approach:
setting priorities for patient care, assessing patients’ speciﬁc educa-
tional needs and identiﬁcation of drug-related problems, develop-
ment of a comprehensive and achievable PC plan in collaboration
with the patient and the physician, implementation of this plan, and
monitoring and review of the plan from time to time [19]. The
nurses collaborated with the pharmacists in terms of organizing the
patients and patients’ folders, taking point-of-care testing, counsel-
ing the patients, and reinforcing the information given to the
patients during training sections. The physicians provided the
visitation/appointment schedule for the patients, and prescription
of laboratory tests. They were also involved in the implementation
of consensus strategies in managing drug-related problems in areas
of changing, substitution, and withdrawal of medications. All the
members of the health care team were trained before the imple-
mentation of the intervention.
The medical and educational contents of the training materials
were evaluated by the physicians and nurses in diabetes clinics
before the researchers conducted the training for the patients. The
physicians and nurses were asked to rate the materials as being
excellent, very good, good, fair, poor, and useless.
The monthly educational/training program for the patients
consisted of four sections of 90 to 120 minutes. The program
covered the following areas: diabetes overview and its complica-
tions, self-monitoring blood glucose techniques and interpreta-
tion of diabetes-related tests, medications and their side effects,
lifestyle modiﬁcation, counseling, and effective interaction with
health providers. PC provided ground for the patients to monitor
and react to changes in their blood glucose levels, allowing them
to integrate their diabetes into the lifestyle they preferred.
Data Collection
Data were collected on utilization of health care resources for 12
months for control and intervention groups at baseline, 6 months,
and 12 months. Information was obtained on the frequency of
self-monitoring, number and average duration of visits to a
hospital, daily doses of drugs taken regularly, and the variable of
“other health care resource use,” including primary care (general
practitioner and nurse consultations), hospital care (visits to an
accident and emergency department, outpatient care, day hospital
care, and inpatient care), auxiliary health care (services of a
podiatrist, optician, or dietitian), and private health care. These
data were collected by means of patients’ PC diaries notes
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medical records.
Patient-speciﬁc data on the incremental resources required
for intervention and control groups and the resources associated
with the treatment of complications were taken. Treatment
resources included doses of drugs used for treating diabetes,
antihypertensive drugs, other drugs, blood-glucose tests, self-
monitoring resources such as test strips, lancets, and glucome-
ters, and visits to general practitioners, practice nurses, and
clinics. Resources associated with complications included the
number, duration, and specialty of admissions to hospital; out-
patient consultations; medical procedures such as photocoagu-
lation and cataract extraction; and day case episodes. The unit
cost of these resource volumes (drugs and other consumables,
laboratory tests, and specialty care per visit) was derived by using
the National Health Insurance Scheme price list [20] and Interna-
tional Drug Price Indicator Guide 2010 edition [21], and the cost of
all inpatient bed-days and outpatient visits was derived from
World Health Organization-Choosing Intervention that is Cost-
Effective (WHO-CHOICE) [22] unit-cost estimates. Costs of the
management of individual complications were calculated from
activities involved in their management by using the ingredient
approach or activity-based costing as opined by the experts; all
costs were adjusted to 2011 cost [23]. The effect of either a higher
or lower adjustment rate was examined in the sensitivity anal-
ysis. All costs are reported in year 2011 values of Nigerian naira
(NGN 155 ¼ $1).
Each item for resource use was categorized into the “cost of the
intervention,” the “cost of drugs,” and the “cost of other health
care resource use” (including primary care, hospital care, and
auxiliary health care). The costs were calculated by multiplying
the volume of resource use in each category by the associated unit
cost in 2010 prices (Table 1). Average costs were estimated in each
arm of the study for the 12 months of follow-up Table 2.
The impact of the interventions on quality of life was
estimated by using the HUI23S4EN.40Q (developed by HUInc -
Mark index 2&3) questionnaire at baseline, 6 months, and 12
months in accordance with the HUI procedures manual (HUI23-
S4EN.40Q, HUI23-40Q.MNL) [24]. We adopted the QALY [2]
because this measure captures both increases in life expectancy
and improved quality of life that results from the prevention of
complications, providing a composite outcome measure of fatal
and nonfatal events that permits comparison between many
health interventions.
Because the economic evaluation perspective was that of the
health care purchaser, only direct health service costs were
included. These included treatment costs, visits to a nurse or a
general practitioner based on “standard practice” assumptions,
and costs of treating diabetes complications. Not included in this
analysis were nonmedical costs such as out-of-pocket expenses
incurred when visiting clinics, cost of informal care provided by
family members, and production losses resulting from work
absences, long-term disability, or premature death.
Statistical Analysis
Statistical analyses were performed by using the SPSS package,
version 14 (SPSS, Inc., Chicago, IL). An intention-to-treat approach
was used. Data were summarized as means  SD, mean differ-
ences with 95% conﬁdence intervals. Two-sample comparisons
were made by using Student’s t tests for normally distributed
variables or Mann-Whitney U tests for nonnormally distributed
data (0, 6, and 12 months). Comparisons of proportions were
carried out by using chi-square, Fisher’s exact, or McNemar’s
tests. An a priori signiﬁcance level of P less than 0.05 was used
throughout. Based on the overall health-related quality-of-life
score for the patients at baseline, 6 months, and 12 months,QALYs were determined. Areas under the curves were deter-
mined by using WinNonlin standard edition version 2.1 [3,22].
Sensitivity analysis
To address uncertainty around the ICUR, univariate sensitivity
analysis was conducted, where one cost variable was varied at a
time (upper and lower limits) while keeping all other variables
constant at their mean base-case cost. Then, two alternative-case
outcomes of ICUR were generated on the basis of upper and lower
boundaries of 20% of the mean base-case cost.
To assess how a simultaneous change in several variables
(QALYs, total intervention cost, cost of antidiabetes medications,
cost of antihypertensives, cost of antidiabetes antihypertensives
medications, total cost of drugs, hospital care cost, auxiliary
health care cost) affects the cost-utility ratio, a Monte-Carlo
simulation (a type of multivariate sensitivity analysis) was
performed. This technique runs a large number of simulations
(here 1000) by repeatedly drawing samples from probability
distributions of input variables. Thus, it provides a probability
distribution of the output variable; that is, QALYs, incremental
costs, incremental effectiveness, and ICURs. Beta and gamma
distributions were assumed for utility (QALYs) and unit cost,
respectively [25–27].
Given that the interpretation of negative ICURs is ambiguous,
the ICURs were transformed into net monetary beneﬁts (NMBs).
The decision rule used was to adopt the intervention in question
if the NMB is greater than zero. Given that the appropriate value
of λ is unknown, λ was varied from NGN 0 to NGN 450,000. A cost-
effectiveness acceptability curve was generated on the basis of
the distribution of NMB for each λ. A cost-effectiveness accept-
ability curve allows a decision maker to consider whether an
intervention (PC) is cost-effective in relation to the maximum
amount a decision maker is willing to pay for a QALY. A discount
rate of 3% and 6% was used in sensitivity analysis [28].
At each ceiling value for the willingness to pay for a QALY, the
cost-effectiveness curve shows the probability that the treatment
is cost-effective. All calculations were done in Microsoft Excel
2007 (Microsoft Corporation, Redmond, WA).Results
Economic Outcomes
The medical and educational content of the training course was
rated positively by the 17 physicians and 29 nurses: the majority
38 (82.6%) rated the content as “excellent” and the remaining 8
rated the content as “very good” or “good”; only 3 (6.5%) of them
suggested little modiﬁcation or changes.
The number of patients who completed the study and whose
data were analyzed at 6 months and 12 months in UC and PC
arms were 98 (89.09%) versus 102 (92.73%) and 93 (84.55%) versus
99 (90.0%), respectively.
The general cost of care/laboratory cost per patient for UC
versus PC at 12 months was NGN 16,519  7,905 ($107  $51)
versus NGN 17,369  6,673 ($112  $43), P ¼ 0.4208. PC-speciﬁc
cost per patient was NGN 7,345  2,651 ($47  $17), while the
costs of antidiabetes medications for UC and PC arms were NGN
9,703  4,632 ($63  $30) and NGN 7,808  4,183 ($50  $27), P ¼
0.0033, respectively. The cost of antihypertensives for UC was
NGN 6,625  4,691 ($43  $30) while that of PC was NGN 5,155 
2,619 ($33  $17), P ¼ 0.0228. The cost of antidiabetes medications
plus antihypertensives for UC was NGN 16,328  5,086 ($105 
$33) as against NGN 12,963  7,549 ($84  $49) for PC, P ¼ 0.0004.
The cost of other medications was NGN 3,243  2,637 ($21  $17)
and NGN 4,945  1,687 ($32  $11), P o 0.0001, for UC and PC,
respectively.
Table 1 – Categories of resources used and their cost sources.
Cost centers Unit cost in NGN (cost used in study) Source
Intervention
Meter (Acu-check Active) 3,300 Market price
Test strips/50 strips 2,200 Market price
Lancet/200 600 Market price
BP apparatus (Aneroid sphygmomanometer and stethoscope) 2,900 Market price
Training/educational materials 800 Market price
Laboratory tests
Hb A1c 1,700 UNTH
Fasting blood glucose 250 [20]
Liver function test 700 [20]
HDL 400 [20]
LDL 700 [20]
Triglyceride 600 [20]
Total cholesterol 300 [20]
Others 34,000 [20]
Drugs
Oral antidiabetes drugs per tablet 15–60 [20,21]
Human insulin per vial 3,200 [20,21]
Insulin soluble per vial 950 [20]
Insulin zinc per vial
Suspension (insulin zinc suspension)
850 [20]
Antihypertensives (tablet, injection, injection powder, syrup) 5–1,400 [20,21]
Others (tablet, injection, injection powder, syrup) 5–280 [20,21]
Hospital care (per episode)
Emergency care 8,000–20,000 (12,000)† Experts’ opinion (UNTH/NAUTH)
Outpatient care (tertiary hospital) 2,149.50 [22]
Inpatient (per day) (tertiary hospital) 4,404 [22]
Primary care
General practitioner consultation 700 [20]
Nurse consultation 700 [20]
Auxiliary health care (per session)
Dietician 700 [20]
Optician 700 [20]
Podiatrist 700 [20]
Others 700 [20]
Note. NGN 155 ¼ $1.
BP, blood pressure; Hb A1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAUTH, Nnamdi Azikiwe University Teaching Hospital; NGN, Nigerian naira; NHIS,
National Health Insurance Scheme; UNTH, University of Nigeria Teaching Hospital.
 When the individual drug was not in the NHIS price list, the International Drug Price Indicator Guide 2010 edition was used; the total cost of drug category was presented because many drugs
were encountered. The ranges of their prices are represented.
† The price in parentheses was used.
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as against NGN 17,908  8,549 ($116  $55) for PC, P ¼ 0.1549. The
hospital care costs for UC and PC were NGN 10,302  5,657 ($67 
$37) and NGN 9,766  4,234 ($63 ± $27), P ¼ 0.4565, respectively,
while their auxiliary health care costs were NGN 4,060  1,675 and
NGN 8,687 2,365 ($56 ± $15), Po 0.0001, respectively. The total cost
per patient per year was NGN 50,452  35747 ($326 ± $231) for UC
and NGN 61,075  43763 ($394 ± $282), P ¼ 0.1009, for PC (Table 3).
Cost-effectiveness or cost-utility was NGN 78524.51 ($507) per
QALY for UC and NGN 80,098.36 ($517) per QALY for PC, while the
incremental cost and incremental QALY were NGN 10,623 ($69) and
0.12, respectively. Thus, the ICUR was NGN 88,525 ($571) per QALY.
Sensitivity Analysis
The cost-effectiveness plane that was obtained from a Monte
Carlo simulation with 1000 iterations showed that 93.8% of theTable 2 – Baseline characteristics of the patients in PC a
Demographic data UC (n ¼ 110)
Mean age  SD (y) 52.8  8.2
Grouped age: 453 y, n (%) 81 (73.64)
Sex: male, n (%) 49 (44.55)
Level of education, n (%)
Primary school 3 (2.72)
Secondary school 71 (64.55)
University 36 (32.73)
Marital status, n (%)
Currently married 37 (33.64)
Widowed 71 (64.54)
Single 2 (1.82)
Occupation, n (%)
Self-employed 37 (33.64)
Employee 35 (31.82)
Retired 38 (34.54)
Smoking status: smoker, n (%) 34 (30.91)
Duration, mean  SD 4.5  2.2
Duration: ≥5 y, n (%) 62 (56.36)
Family history of diabetes, n (%) 71 (64.55)
Physical activity/exercise, n (%) 18 (16.36)
Comorbidities
Hypertension 60 (54.55)
Congestive heart failure 11 (10.00)
Ischemic heart disease 7 (6.36)
Arthritis 37 (33.64)
≥2 comorbidities, n (%) 72 (65.45)
Overnight hospitalization, n (%) 9 (8.18)
Emergency room, n (%) 1 (0.91)
Use of insulin, n (%) 17 (15.45)
Antidiabetic medications, n (%) 103 (93.64)
Other medications, n (%)
Daily aspirin 43 (39.09)
Diuretics 71 (64.55)
Antihypertensives 98 (89.91)
Lipid-lowering 23 (20.91)
Complications, n (%)
Myocardial infarction 2 (1.82)
Stroke 9 (8.18)
Foot ulcer 2 (1.82)
Blindness 1 (0.91)
Renal failure 3 (2.73)
NGN, Nigerian naira; PC, pharmaceutical care; UC, usual care.
P o 0.05.simulations were within the northeast quadrant, where the PC
intervention resulted in gain in QALY and cost, whereas 5.6% of
the simulations were in the southeast quadrant, where the PC
intervention resulted in gain in QALY and reduced cost. Only 0.5%
of the simulations were within the northwest quadrant, where
the addition of PC resulted in loss in QALY and increased cost.
The 1000 iterations produced an incremental QALY that ranged
from −0.022 to 0.293 and an incremental cost that ranged from
NGN −8,276.40 to NGN 28,294.27 (Fig. 1).
The mean NMB within a willingness to pay of NGN 0 to NGN
450,000 was greater in the PC intervention whatever the willing-
ness to pay was. This result also revealed that 90% of PC
credibility interval was far above the mean of UC though the
interval overlapped with about 5% of the UC (Fig. 2).
The PC intervention led to incremental cost and incremental
QALY/effect of NGN 10,623 and 0.12 QALY gained, respectively,
with an associated ICUR of NGN 88525 per QALY gained. Thend UC arms.
PC (n ¼ 110) P
52.4  7.6 0.708
75 (68.18) 0.373
44 (40) 0.495
0.406
6 (5.45)
63 (57.27)
41 (37.27)
0.409
46 (41.82)
63 (57.27)
1 (0.91)
0.611
34 (30.91)
42 (38.18)
34 (30.91)
21 (19.09) 0.043
4.8  2.8 0.378
71 (64.55) 0.215
62 (56.36) 0.214
23 (20.91) 0.387
73 (66.36) 0.073
15 (13.64) 0.404
8 (7.27) 0.789
43 (39.09) 0.400
81 (73.64) 0.187
7 (6.36) 0.604
2 (1.82) 0.561
13 (11.82) 0.432
107 (97.27) 0.195
57 (51.82) 0.058
84 (76.36) 0.055
78 (70.91) 0.0007
14 (12.73) 0.105
4 (3.64) 0.408
6 (5.45) 0.422
3 (2.73) 0.651
1 (0.91) 1.000
8 (7.27) 0.122
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sensitivity analysis, which made the ICUR moved from NGN
88,525 per QALY gained to upper and lower limits of NGN
252,173 per QALY gained and NGN 54,777 per QALY gained,
respectively. When a 3% and 6% adjustment rate of costs was
applied, the lower and upper extremes of ICURs were NGN 85,936
per QALY gained and NGN 88,799 per QALY gained from the base
value of NGN 88,525 per QALY gained.
Varying the base costs by 20% (lower limit to upper limit) and
using these extreme values in simulations, the total intervention
costs center produced ICURs that ranged from NGN 47,426.41 to
NGN 126,544.5 per QALY gained. The antidiabetes cost center
produced ICURs that ranged from NGN 74,817.97 to NGN
104,206.6 per QALY gained. The ICURs moved from NGN 79,210.06
to NGN 98,038.14 per QALY gained when the base cost of the
antihypertensives cost center was varied. The antidiabetes medi-
cations plus antihypertensives produced ICURs that ranged from
NGN 70,020.39 to NGN 109,161.3 per QALY gained, and total drug
cost center produced ICURs that ranged from NGN 58,950.02 to
NGN 120,469.9 per QALY gained. The ICURs of hospital care cost
and auxiliary health care centers ranged from NGN 72,582.82 to
106,161.6 per QALY gained and NGN 74,454.77 to 105,414.0 per
QALY gained, respectively, when base costs of the cost centers
were varied. The ICUR was most sensitive to variation in QALY and
“total intervention-speciﬁc cost center” variable followed by that of
total drug cost center (Fig. 3). In the cost-effectiveness acceptability
curve, the probability that PC was cost-effective versus UC was 95%
at the threshold of NGN 250,000 per QALY gained and 52% at the
threshold of NGN 88,600 per QALY gained (Fig. 4).Discussion
Quality-Adjusted Life-Years
QALYs associated with PC were signiﬁcantly higher than those
associated with UC after 12 months. This indicates that extend-
ing this study beyond 1 year could offer more beneﬁts to patients
with diabetes in terms of QALYs gained. Some studies had
demonstrated that extension of PC beyond 1 year could offer
extra beneﬁts to patients with diabetes [29,30].Table 3 – Costs and QALY per patient per year at the end
155 ¼ $1).
Cost per patient per year UC P
General intervention and laboratory
cost
16,519  7,905 17,369 
Speciﬁc intervention cost for PC NA 7,345 
Total cost of intervention 16,519  7,905 24,714 
Antidiabetes medications 9,703  4,632 7,808 
Antihypertensives 6,625  4,691 5,155 
Antidiabetes medications plus
antihypertensives
16,328  5,086 12,963 
Other medications 3,243  2637 4,945 
Total drug cost 19,571  7514 17,908 
Hospital care cost 10,302  5,657 9,766 
Auxiliary health care cost 4,060  1,675 8,687 
Total cost per patient 50,452  35,747 61,075 
QALY per patient per year 0.6425  0.13 0.7625 
CI, conﬁdence interval; NA, not applicable; PC, pharmaceutical care; QAL
 P ≤ 0.05; Negative cost differences indicate cost savings associated witAt the end of this period, the PC intervention resulted in an
incremental gain in QALYs and cost compared with the UC. This
economic evaluation demonstrates that PC is the most cost-
effective strategy for managing patients with type 2 diabetes if
the patients are willing to pay at least NGN 88,600 per QALY
gained. The addition of the PC intervention to UC, as noted in this
study, should be considered a highly cost-effective management
option for patients with type 2 diabetes because treatments
costing no more than £20,000 (NGN 4,761,905) to £30,000 (NGN
7,142,857) per QALY gained are generally considered to be cost-
effective [1,31]. This PC intervention also generated greater NMBs
when compared with UC; therefore, the addition of PC to UC
might be considered an appropriate management option for
patients with diabetes who have comorbidities where the prob-
ability or likelihood of drug-related problem is higher.
Cost-Effectiveness Plane
The cost-effectiveness plane showed that most of the simula-
tions were within the northeast quadrant, where the addition of
PC to UC resulted in gain in QALY and cost, which indicated that
although the PC intervention generated more QALYs than did UC,
it was more costly. The 1000 iterations showed that the 95%
conﬁdence interval of incremental QALYs and incremental cost
was wide. This wide range shows that there are uncertainties
surrounding both QALYs and cost. The magnitude of QALYs
gained, speciﬁc intervention cost, and cost of all drugs were
found to have affected the ICUR most. This provides avenues for
urgent intervention to reduce the cost of drugs used for the
management of diabetes and its comorbidities and an urgent
institution of intervention that will improve the quality of life of
patients with diabetes in Nigerian tertiary hospitals.
Net Monetary Beneﬁt
The NMB approach provides a useful mechanism for identifying
which arm of the study is most cost-effective. The NMB of additional
PC over UC alone for a willingness to pay of NGN 0 to NGN 450,000,
the additional PC alternative, was associated with the greater mean
NMB whatever the willingness to pay was. It is interesting to note
that the lowest trough (NMB) of PC was far higher than the mean of
UC NMB. Addition of the PC intervention was found to be superior to
UC alone in all willingness to pay, even as the willingness to payof the 12-mo follow-up period for UC versus PC (NGN
C P Mean cost
difference
95% CI per
patient
6,673 0.4208 850 −1,228.1 to 2,928.1
2,651 NA NA NA
11,655 o0.0001 8,195 5,341.9–11,048
4,183 0.0033 −1,895 −3,150.1 to −639.92
2,619 0.0228 −1,470 −2,733.7 to −206.34
7,549 0.0004 −3,365 −5,209.3 to −1,520.7
1,687 o0.0001 1,702 1,074.7–2,328.3
8,549 0.1549 1,663 −3,960.2 to 634.16
4,234 0.4565 −536 −1,952.9 to 880.88
2,365 o0.0001 8,627 8,040.2–9,213.80
43,763 0.1009 10,623 −2,088.5 to 23,335
0.15 o0.0001 0.1200 (0.07–0.1601)
Y, quality-adjusted life-year; UC, usual care.
h the PC intervention.
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Fig. 1 – Cost-effectiveness plane. NGN, Nigerian naira; QALYs, quality-adjusted life-years.
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range of NGN 0 to NGN 450,000, there is a net monetary gain or
saving of NGN 56,148 in 1 year. This amount is more than 3 months
salaries of a Nigerian low-income earner based on the current NGN
18,000 minimumwage [32]. Therefore, there is need for introduction
and exploitation of the PC intervention in Nigerian health facilities
because this is very cost-effective with enormous NMB.Sensitivity Analyses
This study found out that a little variation in QALY gained in PC
to the tune of 10% resulted in a tremendous increase and mild
lowering of the base ICUR, respectively. This result showed that150000
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Fig. 2 – Net monetary beneﬁt of PC and UC at different levels of
pharmaceutical care; QALY, quality-adjusted life-year; UC, usuathe economic burden placed on patients with diabetes by 10%
health deﬁcit was enormous; therefore, interventions such as PC
that would be aimed at improving the quality of life of patients
and resolution/reduction of drug-related problems that would
ultimately reduce the cost of drugs would certainly reduce the
cost per QALY associated with diabetes.
These results indicate that the additional PC intervention has a
cost per QALY gained that is lower than that of UC. In the United
Kingdom, interventions appear to have a high chance of acceptance
by the National Institute for Clinical Excellence if their cost-
effectiveness is more favorable than approximately £30,000 per
QALY [1]. Several other studies had classiﬁed cost-effectiveness.
WHO-CHOICE classiﬁed interventions on the basis of the level of0 250000 300000 350000 400000 450000
s to pay (NGN)
PC
UC
willingness to pay for a QALY. NGN, Nigerian naira; PC,
l care.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 8 9 – 1 9 8196cost-effectiveness by convention as described in the literature [33–
35]. An intervention is cost saving when the intervention generates a
better health outcome and costs less than the comparison inter-
vention. The intervention is cost neutral if the ICER is 0. The
intervention is very cost-effective when the ICER is more than 0 or
$25,000 or less per QALY or life-year gained (LYG) while the
intervention is cost-effective when the ICER is between more than
$25,000 to $50,000 per QALY or LYG. The intervention is marginally
cost-effective when the ICER is between more than $50,000 and
$100,000 per QALY or LYG, whereas an intervention is said to be not
cost-effective when the ICER is more than $100,000 per QALY or LYG.
WHO-CHOICE published in 2005 the cost-effectiveness thresh-
old for different regions of the world. WHO-CHOICE suggested a
cost-effectiveness threshold based on gross domestic product
(GDP) per capita. An intervention that produces cost per QALY
gained of less than GDP per capita of the country is said to be very
cost-effective while an intervention with cost per QALY gained of
between one to three times the GDP per capita of the country is
cost-effective. An intervention with cost per QALY gained of
greater than three times the GDP per capita of the country is
not cost-effective. For AFRO D where Nigeria belongs, the cost-
effectiveness threshold ranges from $1,695 to $5,086 [7]. With a
conversion factor of NGN 155 ¼ $1, the threshold ranges from54,777
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Fig. 3 – Univariate sensitivity analysis of cost and utility variables
QALY, quality-adjusted life-year. A ¼ QALY (10%); B ¼ Adjustmen
D ¼ Cost of antidiabetes medications (20%); E ¼ Cost of antihype
medications (20%); G ¼ Total cost of drugs (20%); H ¼ HospitalNGN 262,725 to NGN 788,330. World Bank in 2010 published a GDP
per capita, considering purchasing power parity-current interna-
tional $; for Nigeria, it is $2,381 (NGN 369,055:00) [34]. The
associated ICUR from this study was NGN 88,525 per QALY
($571.13/QALY) gained in the PC arm, which was far lower than
the GDP per capita of Nigeria in 2010 [36].
Based on the above facts, the PC intervention with an ICUR of
NGN 88,525 per QALY gained is very cost-effective although this
may still not be affordable for low-income earners in relation to the
NGN 18,000 minimum wage approved in Nigeria in 2011 because
NGN 88,525 is about 5 months’ salary of this group of Nigerians [32].
In probabilistic sensitivity analysis, based on the cost-
effectiveness acceptability curve, the PC dominated UC at the
threshold of NGN 88,600 per QALY gained and the probability of
PC being more cost-effective approached 95% at the threshold of
NGN 250,000 per QALY gained. Nevertheless, if a patient is willing
to pay NGN 400,000 per QALY gained, the probability that PC is
the most cost-effective option for managing patients with dia-
betes increases to 97%. In contrast, the probability that UC is the
most cost-effective option at the threshold of NGN 400,000 per
QALY gained approaches zero.
Studies of this kind must address inherent potential threats
to internal validity [37,38]. The major limitations of this study9,210
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 1 8 9 – 1 9 8 197were missing data, selection bias, short period of study, attrition,
and consideration of only direct cost. Data on humanistic
outcome measures were self-reported; however, self-reported
data about diabetes status have been established to be both
valid and reliable [39]. We recommend that future research
studies of this kind address these limitations. This pharmaceut-
ical intervention could be adopted for patients suffering from
other chronic diseases such as HIV, hypertension, asthma,
psychosis, epilepsies, and cerebrovascular and cardiovascular
diseases.Conclusions
The PC intervention was very cost-effective among patients with
type 2 diabetes at the NGN 88,525 ($571.13) per QALY gained
threshold, although considerable uncertainty surrounds these
estimates. This study also revealed that cost incurred and QALYs
gained by patients in the PC group were higher than those of their
counterparts in the UC group. This indicates that the extra cost
paid for extra QALYs gained is worth it because it saves future
expenditures and improves the quality of life of patients.
The results of this study illustrate a convincing economic ration-
ale for improving standards of care for patients with type 2 diabetes
through the PC intervention. This study provides further evidence
that the cost-effectiveness of interventions to reduce the burden of
diabetes-related complications compares favorably with that of other
accepted uses of health care resources. The results should be of
interest and used by other economists and health service researchers,
and in particular should be considered by decision makers when
considering the allocation of resources to diabetes care.
Cost-utility analysis thus increasingly facilitates the trans-
parency of resource allocation processes. The usefulness of cost-
utility analysis to decision makers explains the rapid expansion
in the utilization of cost-utility analysis over the last decade.Acknowledgment
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